Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

北京市春立正達醫療器械股份有限公司
Beijing Chunlizhengda Medical Instruments Co., Ltd.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1858)

(1) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND RULES OF PROCEDURES AND PROPOSED ABOLISHMENT OF THE SUPERVISORY COMMITTEE
(2) PROPOSED AMENDMENTS TO INTERNAL MANAGEMENT POLICIES

This announcement is made by Beijing Chunlizhengda Medical Instruments Co., Ltd.* (the "**Company**") pursuant to Rules 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**").

In order to comply with (i) the amendments to the Company Law of the People's Republic of China (《中華人民共和國公司法》) adopted on 29 December 2023 having come into effect on 1 July 2024, and (ii) the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited having included provisions in respect of the expansion and further expansion of the paperless listing regime, the board of directors of the Company (the "**Board**") hereby announces that it considered and approved the resolutions in relation to the proposed amendments to the articles of association (including the amendments to the rules of procedures for the general meetings and the rules of procedures for the board meetings ("**Rules of Procedures**") which are appendices thereto) of the Company (the "**Proposed Amendments to the Articles of Association and Rules of Procedures**") and the proposed amendments to certain internal management policies (collectively, the "**Internal Management Policies**") to align with the Proposed Amendments to the Articles of Association and Rules of Procedures.

* *For identification purposes only*

The main details of the Proposed Amendments to the Articles of Association and Rules of Procedures include, among others, to the abolishment of the supervisory committee of the Company (the "**Proposed Abolishment of the Supervisory Committee**") and its functions and powers shall be exercised by the audit committee of the Company and to align with the regulatory requirements regarding the expanded paperless listing regime and the electronic dissemination of corporate communications by listed issuers.

In accordance with the articles of association of the Company and the relevant laws and regulations, the Proposed Amendments to the Articles of Association and Rules of Procedures are subject to approval by a special resolution of the shareholders of the Company (the "**Shareholders**") at the extraordinary general meeting (the "**EGM**"), A shareholders' class meeting and H shareholders' class meeting of the Company respectively**.**

The proposed amendments to the following internal management policies of the Company are subject to the approval of the Shareholders at the EGM by way of ordinary resolution (the "**Proposed Amendments to the Internal Management Policies**"):

(1) working system for independent directors; and
(2) management measures for use of proceeds.

A circular containing, among others, details of the Proposed Amendments to the Articles of Association and Rules of Procedures and Proposed Amendments to the Internal Management Policies, together with a notice convening the EGM and the H shareholders' class meeting, has been published on the Company's website at www.clzd.com and the Stock Exchange's website at www.hkexnews.hk.

On behalf of the Board
Beijing Chunlizhengda Medical Instruments Co., Ltd.*
Shi Wenling
Chairman

Beijing, the PRC, 30 October 2025

As at the date of this announcement, the executive Directors of the Company are Ms. Shi Wenling, Mr. Shi Chunbao, Ms. Yue Shujun and Mr. Xie Feng Bao; the non-executive Director of the Company is Mr. Wang Xin; and the independent non-executive Directors of the Company are Ms. Xu Hong, Mr. Wong Tak Shing and Mr. Weng Jie.

* *For identification purposes only*